Phase 1 N=59 Safety Tolerability & Pharmacokinetics of Co-administered Single Doses of OZ439 & Piperaquine to Healthy Subjects
Healthy
Primary: OZ439 Cmax — 142; 139; 146; 198 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=12 Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa
Parkinson's Disease (PD)
Primary: Cmax - Maximum Observed Plasma Concentration — 716; 673; 570; 554 ng/mL
Phase 1 N=42 Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Flow Mediated Vasodilation (FMD) Under Fasted Condition on Day 28 — 0.885; 1.002; 1.002 percentage — p=0.5403
Phase 1 N=25 A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects
Healthy
Primary: Safety of Escalating Multiple Doses of N6022 in Healthy Subjects — 7; 6; 6; 6 participants
Phase 1 N=86 Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies
Neoplasm
Primary: Maximum Tolerated Dose (MTD) — 100 mg
Phase 1 N=76 Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL
Non-Hodgkin's Lymphoma, Relapsed
Primary: Number of Participants With Adverse Events — 12; 13; 6; 9 participants
Phase 1 N=16 Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide
Parkinson's Disease (PD)
Primary: Maximum Observed Plasma Drug Concentration (Cmax) — 1.28; 1.45; 1.42; 0.439 ng/mL
Phase 1 N=16 Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment
Parkinson's Disease
Primary: Cmax - Maximum Plasma Concentration of BIA 9-1067 — 1108; 559 ng/mL
Phase 1 N=445 Clinical Investigation of Expanded Designs of a Multifocal IOL
Cataract
Primary: Mean Monocular Distance-corrected Near Visual Acuity (VA) at 40 cm — 0.253; 0.179; 0.582 LogMAR VA
Phase 1 N=23 A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors
Metastatic or Unresectable Solid Tumor Malignancy
Primary: Dose Determination — 70; 1250 mg/m^2
Phase 1 N=18 Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: To Determine the Maximum Tolerated Dose (MTD) of the Combination of OSI-906 and Everolimus for the Treatment of Patients With Refractory Metastatic Colorectal Cancer…
Phase 1 N=24 Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young Subjects
Parkinson Disease
Primary: Cmax - Maximum Plasma Concentration — 407.4; 391.1; 439.6; 382.0 ng/mL
Phase 1 N=107 Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus
Diabetes Melliuts, Type 2
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 11; 15; 10; 13 participants
Phase 1 N=12 Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers
Hereditary Angioedema (HAE)
Primary: Peak Plasma Concentration (Cmax) of Icatibant and Metabolites — 1190; 340; 365 ng/mL
Phase 1 N=19 Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate in Patients With Stable Severe Renal Disease.
Renal Insufficiency, Chronic
Primary: Cmax,ss — 207 ng/mL — p=0.5186